A “Global Solution” for innovating the diagnosis of drug-resistant tuberculosis.
- Dual-target detection, solving the problem of drug resistance
Synchronous identification of Mycobacterium tuberculosis (MTB) and rifampicin resistance gene (rpoB mutation), the total coincidence rate of Mycobacterium tuberculosis detection was 99.38%, and the coincidence rate of rifampicin resistance was 100%.
- Fast diagnosis, fully enclosed operation
Integrating sample lysis, nucleic acid extraction and amplification detection, it follows the process of “sample in – result out”, with an efficiency improvement of over 90% compared to traditional methods, facilitating same-day diagnosis and treatment in clinical practice.
Independent testing channels support “hands-on testing”, reducing patients’ waiting time and the risk of hospital infection.
- The samples are flexibly adapted to meet the needs of all scenarios.
In addition to sputum, nucleic acid testing can be compatible with over 20 types of samples such as alveolar lavage fluid, gastric liquid, pathological tissue, and cerebrospinal fluid, thereby increasing the positive detection rate of etiology for extrapulmonary tuberculosis, childhood tuberculosis, and negative pulmonary tuberculosis.
Ending the tuberculosis epidemic, begins with every precise diagnosis.
